|
Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …
Jutia Group Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical … |
Kids who play outside less likely to get fatty liver disease – India.Com Health
India.Com HealthKids who play outside less likely to get fatty liver diseaseIndia.Com Healthplaying kid Parents, let the kids play in the sun if you want them to keep non-alcoholic fatty liver disease (NAFLD) at bay as a research has confirmed links be…
Cambridge-US antibodies alliance – Business Weekly
|
Cambridge-US antibodies alliance
Business Weekly MacroGenics has two antibody technology platforms, a Dual-Affinity Re-Targeting (DART™) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimised antibodies with improved effector function. |
Long-Term Outcomes from Cytori Cell Therapy Trial for Heart Failure Published … – MarketWatch
Long-Term Outcomes from Cytori Cell Therapy Trial for Heart Failure Published …MarketWatchSAN DIEGO, Apr 14, 2014 (BUSINESS WIRE) — Cytori Therapeutics (NASDAQ:CYTX) today announced publication of safety and efficacy data from a 36 month European cl…
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio … – The Herald | HeraldOnline.com (press release)
|
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
The Herald | HeraldOnline.com (press release) Daclizumab high-yield process (DAC HYP) is in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at high levels on … Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …Jutia Group |
Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting – Benzinga
|
Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting
Benzinga … beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033). |
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio … – MarketWatch
|
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
MarketWatch Daclizumab high-yield process (DAC HYP) is in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at high levels on … Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …Jutia Group |
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio … – Business Wire (press release)
|
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
Business Wire (press release) … beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033). |
Galaxy S5 joins race to monitor heart rate – Indileak
Indileak |
Galaxy S5 joins race to monitor heart rate
Indileak The latest on the block is Samsung’s new flagship Galaxy S5 smart phone with heart rate monitor that would track your motions and monitor your steps. The innovation comes after Samsung introduced eye-tracking technology last year to pause your phone … Samsung’s S5 breaks S4’s first day sales recordIndia Today Galaxy S5 to have heart rate monitorIndia.Com Health Samsung Galaxy S5, Packs A Storm In PlasticSiliconindia.com CrazyEngineers –Firstpost all 1,732 news articles » |
HSJ Live 14.04.2014: Twenty pilots selected for extended hours fund – Health Service Journal
HSJ Live 14.04.2014: Twenty pilots selected for extended hours fundHealth Service JournalWe cannot afford to neglect the kind of surgical innovation that has made such a difference to a chance of survival and recovery, for example, in keyhole surgery, …